We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Anticancer Therapies – Products

Product News

First Patients are Vaccinated in IMPRINT, immatics’ Pivotal Phase III Trial with IMA901 in Patients with RCC

The trial is designed to demonstrate the overall survival benefit of IMA901 in combination with standard first-line therapy in RCC patients.
Product News

Adaptimmune Announces Opening of Phase I/II Clinical Trial for Metastatic Melanoma at Washington University, St. Louis

Trial could generate future alternative treatment for metastatic melanoma.
Product News

Pharmanet Collaborates with the Cancer Immunotherapy Trials Network

PharmaNet collaborate with CITN to help identify trials with immunotherapy agents prioritized by the CITN as having high potential for cancer therapy.
Product News

YM BioSciences Provides Update on the Development Program for Nimotuzumab

Eleven abstracts on nimotuzumab to be presented at ASCO.
Product News

Thermo Scientific Introduces New Capabilities for Comprehensive Qualitative and Quantitative Proteomics at ASMS 2011

Integrated capabilities offer deeper, broader understanding of proteomes and biological pathways.
Product News

Benitec’s Gene Silencing Technology Used by Johns Hopkins’ Scientists in the Development of a Treatment for Radio-Resistant Prostate Cancer

Researchers in the US used a form of Benitec’s ddRNAi as a key component of their therapeutic molecule in preclinical studies both in vitro and in vivo.
Product News

RPC to Exhibit Onko-Sure® Cancer Test at the ASCO Annual Meeting

Marks RPC's 3rd medical conference participation this year.
Product News

Cytheris and CITN Announce Selection of Recombinant Interleukin-7 (CYT107) for Initial Studies at Member Institutions

Network consists of 27 institutions with the goal of making effective immunotherapy agents broadly available for treatment of cancer.
Product News

Cytheris, Centre Léon Bérard and ImmunID Announce Initiation of Clinical Trial to Evaluate Combination Regimen of IL-7 and XELODA® in Treatment of Metastatic Breast Cancer

Phase IIa study will investigate the optimal schedule for delivery of CYT107 and its ability to prevent or reverse the effects of chemotherapy-induced lymphopenia characterized by a low CD4 T cell count, identified as an independent prognostic factor for overall survival in patients with advanced cancers.
Product News

Roche’s RTCA HT Instrument Adapts Real-Time Cell Analysis to a High-Throughput Format

RTCA HT Instrument´s design allows for integration with automated plate and liquid handling systems.
Advertisement